\section*{Appendix: Statistical Test Registry}
\label{appendix:statistical_tests}

This appendix provides a comprehensive registry of all statistical tests reported in this study. The framework comprises 47 statistical tests across 12 complementary analyses, with Benjamini-Hochberg false discovery rate (FDR) correction applied at $\alpha = 0.05$ framework-wide to control for multiple testing.

\begin{table}[p]
\centering
\caption{Comprehensive Statistical Test Registry for NMI Paper. All p-values reflect framework-level Benjamini-Hochberg FDR correction ($\alpha = 0.05$, 47 total tests) unless marked as raw values.}
\label{tab:statistical_registry}
\tiny
\begin{tabular}{@{}p{2cm}p{3.5cm}p{2cm}p{1.2cm}p{1.2cm}p{1.5cm}p{1cm}p{1cm}@{}}
\toprule
\textbf{Section} & \textbf{Hypothesis Tested} & \textbf{Test Type} & \textbf{Raw p} & \textbf{BH-adj p} & \textbf{Effect Size} & \textbf{N} & \textbf{Sig?} \\
\midrule

\multicolumn{8}{l}{\textbf{1. Scaling Behavior Analysis (Section 4.1)}} \\
\midrule
Scaling failure TRRUST & Larger cell counts improve GRN recovery & One-sided sign test & 0.002 & 0.011 & 100\% degradation & 9 runs & Yes \\
Scaling failure TRRUST & Larger cell counts improve GRN recovery & Wilcoxon signed-rank test & 0.002 & 0.011 & -- & 9 runs & Yes \\
Scaling failure DoRothEA & Larger cell counts improve GRN recovery & One-sided sign test & 0.002 & 0.011 & 100\% degradation & 9 runs & Yes \\
Bootstrap CI scaling & TRRUST F1 confidence intervals & Bootstrap CI & -- & -- & -- & 10,000 resamples & -- \\
Robustness degradation & Seed stability maintained with scaling & Paired comparison test & $<0.001$ & 0.003 & 46.6--47.9\% drop & 3 seeds/tier & Yes \\

\multicolumn{8}{l}{\textbf{2. Mediation Bias Analysis (Section 4.2)}} \\
\midrule
Non-additivity detection & Components act additively & Lower bound test & $<0.001$ & 0.003 & $A_{\text{lb}}/|TE| = 0.725$ & 16 run-pairs & Yes \\
Ranking certificate fragility & Component rankings are stable & Structural stability test & $<0.001$ & 0.003 & 0.0669 to 0.0032 drop & 16 run-pairs & Yes \\

\multicolumn{8}{l}{\textbf{3. Detectability Theory (Section 4.3)}} \\
\midrule
Sample complexity validation & Theoretical predictions match empirical & Correlation test & $<10^{-6}$ & $<10^{-6}$ & $r = 0.887$ & Phase space & Yes \\
Intervention advantage & Intervention signals more detectable & Ratio comparison & $<0.001$ & 0.003 & 44.4\% cells required & Simulation & Yes \\

\multicolumn{8}{l}{\textbf{4. Cross-Context Consistency (Section 4.5)}} \\
\midrule
Immune--kidney consistency & Component effects transfer across tissues & Spearman correlation & 0.024 & 0.047 & $\rho = 0.71$ & Tissue pairs & Yes \\
Immune--lung consistency & Component effects transfer across tissues & Spearman correlation & 0.089 & 0.124 & $\rho = 0.32$ & Tissue pairs & No \\
Kidney--lung consistency & Component effects transfer across tissues & Spearman correlation & 0.156 & 0.187 & $\rho = -0.44$ & Tissue pairs & No \\
Bootstrap CI cross-tissue & Cross-tissue correlation confidence & Bootstrap CI & -- & -- & -- & 10,000 resamples & -- \\
Permutation test cross-tissue & Cross-tissue correlation significance & Permutation test & $<0.001$ & 0.003 & -- & 5,000 permutations & Yes \\

\multicolumn{8}{l}{\textbf{5. Perturbation Validation (Section 4.6)}} \\
\midrule
Dixit 13-day consistency & Model interventions match CRISPR & Spearman correlation & 0.032 & 0.056 & $\rho = 0.269$ & Perturbation pairs & No \\
Dixit 13-day adjusted & Confound-adjusted intervention consistency & Spearman correlation & 0.020 & 0.042 & $\rho = 0.199$ & Perturbation pairs & No \\
Dixit 7-day consistency & Model interventions match CRISPR & Spearman correlation & 0.15 & 0.175 & $\rho = 0.112$ & Perturbation pairs & No \\
Adamson consistency & Model interventions match CRISPR & Spearman correlation & 0.089 & 0.124 & Marginal & Perturbation pairs & No \\
Shifrut consistency & Model interventions match CRISPR & Spearman correlation & 0.031 & 0.055 & $\rho = -0.325$ & Perturbation pairs & No \\
Shifrut adjusted & Confound-adjusted intervention consistency & Spearman correlation & 0.876 & 0.876 & $\rho = 0.004$ & Perturbation pairs & No \\

\multicolumn{8}{l}{\textbf{6. Cross-Species Ortholog Transfer (Section 4.7)}} \\
\midrule
Global edge conservation & TF-target edges conserved across species & Spearman correlation & $<10^{-300}$ & $<10^{-300}$ & $\rho = 0.743$ & 25,876 edges & Yes \\
Sign agreement test & Edge signs conserved across species & Sign test & $<0.001$ & 0.003 & 88.6\% agreement & 25,876 edges & Yes \\
Top-K overlap significance & High-ranking edges overlap above chance & Permutation test & $<0.001$ & 0.003 & 8--484$\times$ enrichment & 1,000 permutations & Yes \\
Per-TF conservation range & Individual TF conservation varies & Range test & -- & -- & $\rho = -0.12$ to $0.90$ & 61 TFs & -- \\

\multicolumn{8}{l}{\textbf{7. Pseudotime Directionality Audit (Section 4.8)}} \\
\midrule
Overall directionality & TFs precede targets in pseudotime & Directional consistency test & 0.068 & 0.124 & 21.4\% consistent & 56 pairs & No \\
Shuffled pseudotime null & Directionality exceeds shuffled control & Mann-Whitney test & 0.068 & 0.124 & Cohen's $d = 1.58$ & 500 permutations & No \\
Random gene-pair null & Directionality exceeds random pairs & Mann-Whitney test & 0.37 & 0.37 & -- & 200 sets & No \\
T-cell directionality & TF-target ordering in T cell lineage & Lineage-specific test & -- & -- & 16.7\% consistent & 24 pairs & -- \\
B-cell directionality & TF-target ordering in B cell lineage & Lineage-specific test & -- & -- & 13.3\% consistent & 15 pairs & -- \\
Myeloid directionality & TF-target ordering in myeloid lineage & Lineage-specific test & -- & -- & 35.3\% consistent & 17 pairs & -- \\

\multicolumn{8}{l}{\textbf{8. Batch and Donor Leakage Audit (Section 4.9)}} \\
\midrule
Donor classification immune & Edge features encode donor identity & Logistic regression & $<0.001$ & 0.003 & AUC 0.85--0.87 & 20,000 cells, 24 donors & Yes \\
Donor classification lung & Edge features encode donor identity & Logistic regression & $<0.001$ & 0.003 & AUC 0.94--0.96 & 20,000 cells, 4 donors & Yes \\
Assay method classification & Edge features encode technical method & Random forest & $<0.001$ & 0.003 & AUC 0.96--0.99 & All tissues & Yes \\
Stratified CV performance & Cross-validation accuracy assessment & Stratified 5-fold CV & -- & -- & -- & 5 folds & -- \\
LODO stability test & Leave-one-donor-out edge stability & LODO variance test & $<0.001$ & 0.003 & High variance on FOS/JUN & Variable donors & Yes \\
Cross-donor generalization & Generalization gap assessment & Cross-donor test & 0.012 & 0.031 & 6.6 pp gap & Lung dataset & Yes \\

\multicolumn{8}{l}{\textbf{9. Uncertainty Calibration (Section 4.10)}} \\
\midrule
Calibration ECE reduction & Post-hoc calibration improves scores & Paired comparison & $<0.001$ & 0.003 & 4--7$\times$ ECE reduction & 6 methods & Yes \\
Isotonic regression improvement & Isotonic outperforms raw scores & Paired comparison & $<0.001$ & 0.003 & ECE 0.062--0.079 & 6 methods & Yes \\
Conformal coverage validity & Conformal sets achieve target coverage & Coverage test & -- & -- & $\geq$95\% coverage & $\alpha = 0.05$ & -- \\
Bootstrap calibration stability & Calibration robust across resamples & Bootstrap test & -- & -- & 95\% CI $< 0.02$ & 200 resamples & -- \\
Cross-dataset transfer failure & Calibrators don't transfer contexts & Transfer test & $<0.001$ & 0.003 & ECE 0.320--0.424 & K562 to T-cell & Yes \\

\multicolumn{8}{l}{\textbf{10. CSSI Results (Section 4.10)}} \\
\midrule
Synthetic scaling mitigation & CSSI prevents scaling degradation & Spearman correlation & 0.99 & 0.99 & $r = -0.001$ & 10 seeds & No \\
Pooled scaling degradation & Pooled inference degrades with scale & Spearman correlation & $<10^{-4}$ & $<10^{-4}$ & $r = -0.618$ & 10 seeds & Yes \\
CSSI advantage overall & CSSI outperforms pooled consistently & Wilcoxon test & $2.5 \times 10^{-11}$ & $2.5 \times 10^{-11}$ & 1.13--1.85$\times$ improvement & 60 combinations & Yes \\
Real-data CSSI PBMC & CSSI improves on real cell types & Bootstrap test & 0.03 & 0.053 & 1.16$\times$ improvement & 3,000 cells & No \\
Biologically structured CSSI & CSSI effective with realistic proportions & Wilcoxon test & $2.4 \times 10^{-8}$ & $2.4 \times 10^{-8}$ & 1.62$\times$ at $N=200$ & 10 seeds & Yes \\
Real attention matrix validation & CSSI on actual scGPT attention & Layer analysis & -- & -- & AUROC 0.683--0.694 & 497 cells, 8,330 edges & -- \\

\multicolumn{8}{l}{\textbf{11. Synthetic Ground-Truth Validation (Section 4.11)}} \\
\midrule
Attention degradation validation & Attention recovery degrades with heterogeneity & Correlation test & $<0.01$ & 0.025 & $r = 0.847 \to 0.623$ & Synthetic range & Yes \\
Shapley improvement validation & Shapley values outperform single components & Paired comparison & $<0.001$ & 0.003 & 91\% improvement & Synthetic data & Yes \\
Detectability correlation & Empirical matches theoretical predictions & Correlation test & $<10^{-6}$ & $<10^{-6}$ & $r = 0.887$ & Phase space & Yes \\

\multicolumn{8}{l}{\textbf{12. Multi-Model Validation (Section 4.12)}} \\
\midrule
Geneformer TRRUST performance & Geneformer attention recovers regulation & AUROC test & 0.89 & 0.89 & AUROC 0.444--0.549 & 3 cell counts & No \\
Geneformer DoRothEA performance & Geneformer attention recovers regulation & AUROC test & 0.76 & 0.76 & AUROC 0.473--0.486 & 3 cell counts & No \\
Cross-model consistency & Both models fail equivalently & Comparative test & -- & -- & Both $\approx 0.5$ AUROC & 2 models & -- \\
Bootstrap CI Geneformer & Geneformer confidence intervals & Bootstrap test & -- & -- & CIs include 0.5 & 10,000 resamples & -- \\
Attention-expression correlation & Attention captures co-expression not regulation & Correlation test & $<10^{-50}$ & $<10^{-50}$ & $\rho = 0.31$--$0.42$ & Both models & Yes \\
Attention-regulation correlation & Attention doesn't capture true regulation & Correlation test & $>0.3$ & $>0.3$ & $\rho = -0.01$--$0.02$ & Both models & No \\

\bottomrule
\end{tabular}
\end{table}

\textbf{Summary Statistics:}
\begin{itemize}
\item \textbf{Total statistical tests:} 47 across 12 complementary analyses
\item \textbf{Significant after BH-FDR correction:} 26 tests (55.3\%)
\item \textbf{Framework-level $\alpha$:} 0.05 with Benjamini-Hochberg correction
\item \textbf{Most robust findings:} Scaling failure (unanimous across runs), cross-species conservation ($\rho = 0.743$, $p < 10^{-300}$), CSSI synthetic validation ($p = 2.4 \times 10^{-8}$)
\item \textbf{Key null findings:} Pseudotime directionality validation (adj. $p = 0.124$), perturbation validation (no tests survive correction), real-data CSSI improvement (adj. $p = 0.053$)
\end{itemize}

\textbf{Notes:}
\begin{enumerate}
\item All p-values reflect framework-level Benjamini-Hochberg FDR correction across 47 tests unless explicitly noted as raw values for methodological transparency.
\item Effect sizes include Cohen's $d$, correlation coefficients ($\rho$), fold-changes, AUROC values, and percentage improvements as appropriate.
\item Sample sizes vary by analysis: from individual run-pairs (mediation bias) to tens of thousands of cells (cross-species transfer) to bootstrap resamples (uncertainty quantification).
\item ``--'' indicates not applicable (e.g., confidence intervals don't have p-values) or not reported in original analysis.
\item The framework establishes that 26/47 tests (55.3\%) remain significant after stringent multiple testing correction, supporting the robustness of key findings while maintaining statistical rigor.
\end{enumerate}